Back to Search Start Over

Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011

Authors :
Schoffer, Olaf
Schülein, Stefanie
Arand, Gerlinde
Arnholdt, Hans
Baaske, Dieter
Bargou, Ralf C.
Becker, Nikolaus
Beckmann, Matthias W.
Bodack, Yves
Böhme, Beatrix
Bozkurt, Tayfun
Breitsprecher, Regine
Buchali, Andre
Burger, Elke
Burger, Ulrike
Dommisch, Klaus
Elsner, Gudrun
Fernschild, Karin
Flintzer, Ulrike
Funke, Uwe
Gerken, Michael
Göbel, Hubert
Grobe, Norbert
Gumpp, Vera
Heinzerling, Lucie
Kempfer, Lana Raffaela
Kiani, Alexander
Klinkhammer-Schalke, Monika
Klöcking, Sabine
Kreibich, Ute
Knabner, Katrin
Kuhn, Peter
Lutze, Stine
Mäder, Uwe
Maisel, Tanja
Maschke, Jan
Middeke, Martin
Neubauer, Andreas
Niedostatek, Antje
Opazo-Saez, Anabelle
Peters, Christoph
Schell, Beatrice
Schenkirsch, Gerhard
Schmalenberg, Harald
Schmidt, Peter
Schneider, Constanze
Schubotz, Birgit
Seide, Anika
Strecker, Paul
Taubenheim, Sabine
Wackes, Matthias
Weiß, Steffen
Welke, Claudia
Werner, Carmen
Wittekind, Christian
Wulff, Jörg
Zettl, Heike
Klug, Stefanie J.
Source :
BMC Cancer
Publication Year :
2016

Abstract

Background Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and regional differences in stage distribution and survival of melanoma patients. Methods Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods, joinpoint regression, logistic regression and relative survival. Results The number of annually documented cases increased by 53.2% between 2002 (N = 4 779) and 2011 (N = 7 320). There was a statistically significant continuous positive trend in the proportion of stage UICC I cases diagnosed between 2002 and 2011, compared to a negative trend for stage UICC II. No trends were found for stages UICC III and IV respectively. Age (OR 0.97, 95% CI 0.97–0.97), sex (OR 1.18, 95% CI 1.11–1.25), date of diagnosis (OR 1.05, 95% CI 1.04–1.06), ‘diagnosis during screening’ (OR 3.24, 95% CI 2.50–4.19) and place of residence (OR 1.23, 95% CI 1.16–1.30) had a statistically significant influence on the tumour stage at diagnosis. The overall 5-year relative survival for invasive cases was 83.4% (95% CI 82.8–83.9%). Conclusions No distinct changes in the distribution of malignant melanoma tumour stages among those aged 35 and older were seen that could be directly attributed to the introduction of skin cancer screening in 2008. Electronic supplementary material The online version of this article (doi:10.1186/s12885-016-2963-0) contains supplementary material, which is available to authorized users.

Details

Language :
English
Database :
OpenAIRE
Journal :
BMC Cancer
Accession number :
edsair.pmid.dedup....ec0d87259189887952a30022aab70d23